I don't think it's great for us. One aspect is the approval which bodes well for us for our own pathway but having Mindmed doing relatively the same therapy takes the unique factor away. If I was buying in, this pathway wouldn't be where I would be expecting my investment return. It may have some positive influence on our SP short term as people may see our GAD treatment being derisked. It will all depend on our results vs theirs. If they get to the end first then that softens our impact. Please someone have the opposite view........
IHL Price at posting:
44.0¢ Sentiment: Buy Disclosure: Held
